Moderna said on Monday its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna's flu vaccine candidate, mRNA-1010, shows 26.6% efficacy in a Phase 3 trial for adults 50+. Read more here.

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

Influenza significantly impacted adults aged 50 to 64 years and younger adults with chronic conditions, but risk can be reduced with RIV.

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

New research uses bird droppings to track avian flu in remote regions, revealing hidden hotspots and potential for early ...

A new ESC Clinical Consensus Statement published in the European Heart Journal discusses the key role of vaccination in ...

In a study of newborn piglets, infection with influenza A was associated with disruptions in the piglets' nasal and gut ...

A recombinant flu vaccine (Flublok) contains no eggs and was recently approved for use in individuals aged 9 years or older ...

A new slate of vaccine advisers to the US Centers for Disease Control and Prevention voted Thursday to recommend that ...